Publications by the researcher in collaboration with Javier Pérez Gisbert (18)

2024

  1. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

2022

  1. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  2. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  3. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

  4. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2014

  1. Delphi consensus statement: Quality indicators for inflammatory bowel disease comprehensive care units

    Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 240-251

2012

  1. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

    Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523

  2. Intensification of infliximab therapy in Crohn's disease: Efficacy and safety

    Journal of Crohn's and Colitis, Vol. 6, Núm. 1, pp. 62-67

2011

  1. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Alimentary Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 340-348

  2. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 443-448

2009

  1. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing crohn's disease

    Journal of Clinical Gastroenterology, Vol. 43, Núm. 10, pp. 950-956

2008

  1. Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response

    Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426

  2. Open-label infliximab therapy in ulcerative colitis: A multicenter survey of results and predictors of response

    Hepato-Gastroenterology, Vol. 55, Núm. 86-87, pp. 1609-1614